Search company, investor...
Myst Therapeutics company logo

Myst Therapeutics

myst-tx.com

Stage

Acquired | Acquired

About Myst Therapeutics

Myst Therapeutics is a biotechnology company focused on the development and commercialization of novel broad-spectrum cancer immunotherapy products designed to harness the power of a patient’s own immune system to destroy cancer cells. The company is pursuing the development of an adoptive cell therapy utilizing enriched T cells from tumors and peripheral blood that target a broad spectrum of cancer mutations.On January 20th, 2021, Myst Therapeutics was acquired by Turnstone Biologics. The terms of the transaction were not disclosed.

Headquarters Location

California NanoSystems Institute 570 Westwood Plaza, Building 114

Los Angeles, California, 90095,

United States

Missing: Myst Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Myst Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Myst Therapeutics Patents

Myst Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/18/2020

G protein coupled receptors, Clusters of differentiation, Immune system, Cell surface receptor deficiencies, Immunology

Application

Application Date

2/18/2020

Grant Date

Title

Related Topics

G protein coupled receptors, Clusters of differentiation, Immune system, Cell surface receptor deficiencies, Immunology

Status

Application

Latest Myst Therapeutics News

Turnstone teams up with Moffitt to race TIL cell therapies into the clinic

Nov 29, 2021

Nov 29, 2021 8:15am Turnstone Biologics will provide the Moffitt Cancer Center with financial support for R&D over the course of the multiyear collaboration. (koto_feja) Turnstone Biologics is charging ahead with its expansion into tumor-infiltrating lymphocytes (TILs), striking a deal with the Moffitt Cancer Center to complement the capabilities it picked up in its takeover of Myst Therapeutics at the start of the year. New York-based Turnstone initially made headlines for its work on oncolytic viruses. That modality is still part of the biotech’s plans, with the virus platform providing Turnstone’s most advanced asset, but is now joined by TIL cell therapies. Turnstone plans to take its lead TIL prospect, TIDAL-01, into the clinic early next year. The Moffitt agreement will support the progress of TIDAL-01 and other TIL candidates. Moffitt will work on “the identification, enrichment and expansion of neoantigen reactive TILs in solid tumor indications, including melanoma, breast and colorectal cancers,” and on the production of therapies for use in Turnstone’s clinical trials. The collaboration will cover activities including the IND filing for TIDAL-01. “With Moffitt’s world leading researchers and unique capabilities to support translational research, we believe this collaboration will be crucial in bringing our transformative TIL therapies to people with cancer,” Turnstone CEO Sammy Farah said in a statement.

Myst Therapeutics Frequently Asked Questions (FAQ)

  • Where is Myst Therapeutics's headquarters?

    Myst Therapeutics's headquarters is located at California NanoSystems Institute, Los Angeles.

  • What is Myst Therapeutics's latest funding round?

    Myst Therapeutics's latest funding round is Acquired.

  • Who are the investors of Myst Therapeutics?

    Investors of Myst Therapeutics include Turnstone Biologics.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.